Two antilipidemic compounds, clofibrate and procetofene, inhibited the replication of herpes simplex virus type 1 (HSV-1) in African green monkey kidney cells. Clofibrate, at a concentration of 400 ,umol/liter caused a 63% reduction (P < 0.001) in HSV-1 yield and at 100 pnol/liter caused a 62% reduction (P < 0.001) in plaque formation. Two stereoisomeric analogs of clofibric acid, (-)-and (+)-desmethyl clofibric acid, also caused a significant inhibition of HSV-1 replication.
(42 to 54%) and plaque formation (65%). Procetofene also inhibited the development of HSV-1 plaques. A concentration of 5 ,umol/liter resulted in a 26% reduction (P < 0.001) in plaque diameter. Because of their nonspecific inhibitory effect on the uptake of cellular macromolecular precursors for nucleic acid and protein biosynthesis, these antilipidemic compounds may exert their antiviral activity by affecting one or more key metabolic host cell pathways.
A conceptual basis for using antilipidemic compounds to inhibit virus replication has been suggested by Grossberg and associates (6, 7) , who demonstrated that the sodium salt of clofibrate [sodium 2-(p-chlorophenoxy)-2-methylpropionate; Fig. 1 ] decreased both viral titers and circulating lipid levels associated with arbovirus infections. Steinhart et al. (18) further demonstrated the antiviral efficacy of clofibrate [Atromid S; ethyl 2-(p-chlorophenoxy)-2-methylpropionate; Fig. 1 ] by noting its ability to inhibit herpes simplex virus type 1 replication in vitro at nontoxic concentrations. It has been hypothesized by Grossberg et al. that clofibrate antiviral activity is mediated via lipid biogenesis either in the viral envelope or in the host membranes necessary for viral development (6, 7) . Clofibrate is known to alter cellular lipid metabolism at different levels, suggesting that this drug could deprive replicating viruses of essential lipid components (3, 10, 14, 15, 19, 20) . In addition, Steinhart and associates (18) have demonstrated that clofibrate antiviral activity is directed at some late step in HSV maturation such as during envelopment of the virion by host membranes.
The purpose of this study was Clofibric acid, a gift from G. R. Goetchius (Ayerst Laboratories, Inc.), and the isomeric desmethyl clofibric analog (21, 22) were dissolved in 1.0 N NaOH to make a 0.01 M solution. Each compound was further diluted with tissue culture maintenance medium. For each solution, the final pH was 7.8. As a control, similar alkaline solutions without test compounds were used.
Cytotoxicity assays. The cytotoxic effects of clofibrate and procetofene were determined by monitoring the uptake of macromolecular precursors for deoxyribonucleic acid, protein, and lipid synthesis. The effect of clofibrate and procetofene on uptake of precursors for protein and lipid metabolism was determined because clofibrate is reported to directly affect cell lipid metabolism (3, 10, 14, 15, 19, 20, 23) as well as other metabolic pathways (2, (11) (12) (13) 24 h of any given incubation period. After incubation, cells were trypsinized and collected with a MASH II cell harvester. Exogenous isotope was removed by exhaustive washing with saline. A Beckman LS-7000 liquid scintillation counter was used to determine radioactivity. The percentage of inhibition of 3H-labeled precursor uptake was determined as follows:
( mean cpm of drug-treated cultures mean cpm of non-drug-treated cultures The cytotoxic effects of clofibric and desmethyl clofibric acid analogs were determined as described above or by growth inhibition studies. The inhibition of cell growth was monitored by exposing established BGM-70 cells to various concentrations of compound for 72 h. At 0, 24, 48, and 72 h, mean cell counts from triplet cultures were determined for both drug-treated and nontreated cultures. Results were analyzed by Student's t-test for significant inhibition.
Viral quantitation. Ten-fold dilutions of HSV-1 were plaque assayed in tissue culture dishes (160 by 15 mm; Falcon 3030). A 0.75% methylcellulose overlay was used to prevent the fonnation of secondary foci. A microplaque assay, similar to the one described by Gentry and Aswell (5), was also used to titrate HSV-1. For the microplaque assay, titrations were carried out without an overlay in 24-well cell culture trays (Flow Laboratories, Inc., Linbro Div., Hamden, Conn.). Plaques were counted with the aid of an inverted microscope at 48 h after staining of monolayers with 0.5% crystal violet in 10% formaldehyde.
Yield and plaque reduction assays. Yield reduction assays were performed in tube cultures and in 24- well cell culture trays to mimic the conditions used in the cytotoxicity studies. Cultures were grown to 80 to 90% confluency before virus was allowed to adsorb for 1 h at 37°C. After adsorption, maintenance medium 270 MEHL ET AL.
on November 2, 2017 by guest http://aac.asm.org/ Downloaded from containing drug was added and the cultures were reincubated for 34 to 48 h. The infected cultures were then subjected to three cycles of freeze-thawing, and the resulting supernatants were clarified at 800 x g for 20 min. Supernatants were then titrated for infectious virus.
The plaque reduction assay was performed by adding 75 to 150 plaque-forming units (PFU) of HSV-1 in 50 AJ to monolayers of BGM-70 cells. After adsorption, 1 ml of maintenance medium containing various concentrations of drug was added to respective wells. After 48 h, plaques were enumerated and measured for size with the aid of an inverted microscope.
RESULTS
Cytotoxicity studies. Inhibition of [3H]thymidine uptake was found to be a reliable indicator of toxicity. Figure 2 illustrates the effect of different concentrations of clofibrate and procetofene on [3H]thymidine uptake and demonstrates the relative toxicity of the two compounds. Procetofene was toxic at greater than 5 ,umol/liter, whereas clofibrate was tolerated up to 600 ,umol/liter. This dramatic difference in toxicity was also seen in the ability of these same two compounds to inhibit [3H]acetate and 3H-labeled amino acid uptake. vation that 10 mmol/liter is a concentration 20 times greater than any nontoxic concentration used to inhibit replication of HSV-1 in cell culture. Effect of clofibrate and procetofene on HSV-1 replication. Before determining the antiviral potential of clofibrate and procetofene, a comparison for quantitating v-irus was made between a standard macro-plaque assay and a scaled-down micro-plaque assay. A 0.75% methylcellulose overlay was used for the macroplaque assay; none was used with the microplaque assay. There were no statistical differ--ences in sensitivity between the macro and micro methods (70 ± 12 versus 69 ± 8 PFU/m1 x 105, n = 4). The micro-plaque assay, however, was less expensive and less cumbersome than the standard macro method. By not adding 0.75% active as clofibrate, also caused a significant inhibition of HSV-1 plaque formation (Fig. 3) . At 500 umol/liter, all three clofibric acids had antiviral activity and were found to be nontoxic by our cytotoxicity or growth inhibition assays (data not shown).
Procetofene was also found to inhibit the replication of HSV-1 (Table 3) . A concentration of 5 iLmol/liter gave a 56% reduction (P < 0.001) in plaque formation. At 10 smmol/liter, a significant reduction (P < 0.001) in both viral yield (42 to 54%) and plaque formation (65%) was observed. Procetofene inhibited not only plaque formation, but also plaque size ( (Fig. 2) , it did significantly inhibit (56%) HSV-1 plaque formation (Table 3) and reduce plaque sizes ( Nonspecific effects on macromolecular uptake observed in our toxicity studies also indicate that clofibrate may inhibit a common pathway, as suggested by Pan and Chou (16) in their studies with Tetrahymenapyriformis. Inhibition of uptake of labeled biosynthetic precursors for deoxyribonucleic acid, protein, and lipid biosynthesis may be a secondary effect to inhibition of a more common or key pathway involving cell energetics. Furthermore, it is less likely that the antiviral activities attributable to procetofene and clofibrate are specific because these compounds would lack a high variety of independent and highly specific ligand-enzyme interactions (25) .
The ability of antilipidemic agents to operate on host metabolic pathways common to viral replication suggests that some of these compounds may have potential use against viruses that require essential lipids. Our studies provide evidence that clofibrate or procetofene can produce a protective effect to the advantage of the virus-infected host. Viral strains resistant to these drugs might not result from therapy, because it is unlikely that a viral genome would undergo mutation in response to drug action directed against a normal cell.
